IM Cannabis Corp.

IMCC

CA44969Q3070

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 17:30:17 03/06/2024 BST			5-day change	1st Jan Change
0.78 ^CAD	0.00%		-10.34%	+69.57%

05-29	IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding	CI
05-26	IM Cannabis Corp. announced that it expects to receive CAD 2.091977 million in funding	CI

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

May 12, 2022 at 09:01 pm

IM Cannabis Corp. provided preliminary unaudited revenue guidance for the second quarter 2022. On a preliminary unaudited basis, the company expects second quarter 2022 revenue to increase sequentially.

Latest news about IM Cannabis Corp.

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding	05-28	CI
IM Cannabis Corp. announced that it expects to receive CAD 2.091977 million in funding	05-25	CI
Transcript : IM Cannabis Corp., Q1 2024 Earnings Call, May 08, 2024	05-08
IM Cannabis Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market	04-09	CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market	04-04	MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024	03-28
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023	03-25	MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth	03-25	MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization	03-25	MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis	03-25	CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company	02-28	MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction.	02-27	CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments	02-26	MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule	01-31	MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition	01-12	MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical	01-02	MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months	12-08	MT
IM Cannabis Announces Receipt of Court Action	11-27	MT
Transcript : IM Cannabis Corp., Q3 2023 Earnings Call, Nov 13, 2023	11-13
IM Cannabis Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
IM Cannabis Secures $1.39 Million in Short-Term Debt	13/10/23	MT
IM Cannabis Corp. Announces Executive Changes	10/10/23	CI
IM Cannabis CFO Steps Down	19/09/23	MT

Chart IM Cannabis Corp.

Duration

Period

More charts

Company Profile

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company